JAZZ — Jazz Pharmaceuticals plc
JAZZ dilution and offerings
- Float: 62.2M shares
$214.44-0.71%
Last close: · regular session
After-hours $214.43 -0.00% ·
Last 60 sessions
Float: 62.2M shares. Latest SEC filing: 10-Q on Nov 2, 2026. JAZZ closed at $214.44 (-0.71%) on Nov 2, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for JAZZ in the TickerWise workspace.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: IE
- Exchange: NASDAQ
- Employees: 2,800
- Website: https://www.jazzpharma.com
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.
Latest SEC filings for JAZZ
Latest JAZZ news
- Jazz outlines $4.775B-$4.85B 2026 revenue guidance as Ziihera launch builds toward $3B-$5B peak sales potential Read article
- Jazz (JAZZ) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates Read article
- Jazz Pharmaceuticals Non-GAAP EPS of -$3.88 misses by $1.50, revenue of $1.24B beats by $30M Read article
- Jazz Pharmaceuticals sees $755M IPR&D charge in Q3 results Read article
- Analysts Estimate Jazz Pharmaceuticals (JAZZ) to Report a Decline in Earnings: What to Look Out for Read article
- Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.